Home > Insider Trading > Filing (0001628280-25-030969)

Filing Details

Accession Number:: 0001628280-25-030969
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2025-06-12 16:20:30
Reporting Period:: 2025-06-10

Filing Date:: 2025-06-12
Accepted Time:: 2025-06-12 16:20:30
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1104506	Insmed Inc	INSM	Pharmaceutical Preparations (2834)	541972729

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1401017	Nicole S Orlov Schaeffer	700 Us Highway 202/206 Bridgewater NJ 08807	Chief People Strategy Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2025-06-10	38,300	$17.16	156,879	No	4	M	Direct
Common Stock	Disposition	2025-06-10	38,300	$88.64	118,579	No	4	S	Direct
Common Stock	Acquisiton	2025-06-11	70,000	$13.91	188,579	No	4	M	Direct
Common Stock	Disposition	2025-06-11	35,072	$91.68	153,507	No	4	S	Direct
Common Stock	Disposition	2025-06-11	18,319	$92.73	135,188	No	4	S	Direct
Common Stock	Disposition	2025-06-11	10,781	$93.48	124,407	No	4	S	Direct
Common Stock	Disposition	2025-06-11	34,500	$95.49	89,907	No	4	S	Direct
Common Stock	Disposition	2025-06-11	500	$96.02	89,407	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (right to buy)	Disposition	2025-06-10	38,300	$0.00	38,300	$17.16
Common Stock	Stock Option (right to buy)	Disposition	2025-06-11	70,000	$0.00	70,000	$13.91

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0		2027-05-17	No	4	M	Direct
87,290		2029-01-03	No	4	M	Direct

Footnotes

This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on August 15, 2024, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.
This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on February 26, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.
This is the weighted average sales price representing 35,072 shares sold at prices ranging from $91.18 to $92.17 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.
This is the weighted average sales price representing 18,319 shares sold at prices ranging from $92.20 to $93.19 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.
This is the weighted average sales price representing 10,781 shares sold at prices ranging from $93.20 to $93.77 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.
This is the weighted average sales price representing 34,500 shares sold at prices ranging from $95.00 to $95.99 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.
This is the weighted average sales price representing 500 shares sold at prices ranging from $96.00 to $96.04 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.
The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. All options are currently exercisable.